The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions

Experimental Neurology

Volumn 263, Issue , 2015, Pages 277-284

  Bordia, Tanuja ^a   McGregor, Matthew ^a   Papke, Roger L ^b   Decker, Michael W ^c   Michael McIntosh, J ^d,e,f   Quik, Maryka ^a  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c ABBVIE INC   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF UTAH   (United States)

Author keywords

ABT 107; DMXB; Neuroprotection; Nicotine; Nicotinic receptors; Parkinson's disease

Indexed keywords

ABT 107; BUNGAROTOXIN RECEPTOR; DOPAMINE; DOPAMINE TRANSPORTER; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; OXIDOPAMINE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; 5-(6-(1-AZABICYCLO(2,2,2)OCT-3-YLOXY)PYRIDAZIN-3-YL)-1H-INDOLE; ADRENERGIC RECEPTOR STIMULATING AGENT; INDOLE DERIVATIVE; NEUROPROTECTIVE AGENT; QUINUCLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG MECHANISM; FOREBRAIN; INCIDENCE; LOCOMOTION; MALE; MINIPUMP; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; OSMOTIC MINIPUMP; PARKINSON DISEASE; PARKINSONISM; RAT; STRIATONIGRAL DEGENERATION; AGONISTS; ANIMAL; AUTORADIOGRAPHY; BRAIN; DRUG EFFECTS; METABOLISM; SPRAGUE DAWLEY RAT;

ADRENERGIC AGENTS; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; AUTORADIOGRAPHY; BRAIN; INDOLES; MALE; NEUROPROTECTIVE AGENTS; NICOTINIC AGONISTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; QUINUCLIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84910641282     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.09.015     Document Type: Article

References (63)

1. Betts M.J., et al. Allosteric modulation of the group III mGlu(4) receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease. Br. J. Pharmacol. 2012, 166:2317-2330.
2. Bitner R.S., et al. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J. Pharmacol. Exp. Ther. 2010, 334:875-886.
3. Bordia T., et al. Continuous and intermittent nicotine treatment reduces l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther. 2008, 327:239-247.
4. Bordia T., et al. Nicotinic receptor-mediated reduction in l-dopa-induced dyskinesias may occur via desensitization. J. Pharmacol. Exp. Ther. 2010, 333:929-938.
5. Bordia T., et al. The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release. J. Neurochem. 2013, 125:291-302.
6. Briggs C.A., et al. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav. 1997, 57:231-241.
7. Cenci M.A., Lundblad M. Ratings of l-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr. Protoc. Neurosci. 2007, Chapter 9:1-23.
8. Chang J.W., et al. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 1999, 88:617-628.
9. Chen H., et al. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010, 74:878-884.
10. Dajas-Bailador F.A., et al. The alpha7 nicotinic acetylcholine receptor subtype mediates nicotine protection against NMDA excitotoxicity in primary hippocampal cultures through a Ca(2+) dependent mechanism. Neuropharmacology 2000, 39:2799-2807.
11. de Fiebre N.C., de Fiebre C.M. Alpha 7 nicotinic acetylcholine receptor-mediated protection against ethanol-induced neurotoxicity. Alcohol 2003, 31:149-153.
12. Fahn S. Parkinson's disease: 10years of progress, 1997-2007. Mov. Disord. 2010, 25(Suppl. 1):S2-S14.
13. Fleming S.M., et al. Cranial and related sensorimotor impairments in rodent models of Parkinson's disease. Behav. Brain Res. 2012, 231:317-322.
14. Freedman R., et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am. J. Psychiatry 2008, 165:1040-1047.
15. Gorell J.M., et al. Smoking and Parkinson's disease: a dose-response relationship. Neurology 1999, 52:115-119.
16. Grady S.R., et al. Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions. J. Pharmacol. Exp. Ther. 2002, 301:651-660.
17. Hickey P., Stacy M. AAV2-neurturin (CERE-120) for Parkinson's disease. Expert. Opin. Biol. Ther. 2013, 13:137-145.
18. Hirsch E.C., et al. Pathogenesis of Parkinson's disease. Mov. Disord. 2013, 28:24-30.
19. Huang L.Z., et al. Nicotine is neuroprotective when administered before but not after nigrostriatal damage in rats and monkeys. J. Neurochem. 2009, 109:826-837.
20. Kaiser S., Wonnacott S. Alpha-bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release. Mol. Pharmacol. 2000, 58:312-318.
21. Kaneko S., et al. Nicotine protects cultured cortical neurons against glutamate-induced cytotoxicity via alpha7-neuronal receptors and neuronal CNS receptors. Brain Res. 1997, 765:135-140.
22. Kerr D.S. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol. Genet. Metab. 2010, 99:246-255.
23. Kieburtz K., Wunderle K.B. Parkinson's disease: evidence for environmental risk factors. Mov. Disord. 2013, 28:8-13.
24. Li Y., et al. Alpha7 nicotinic receptor-mediated protection against ethanol-induced oxidative stress and cytotoxicity in PC12 cells. Brain Res. 2000, 861:165-167.
25. Malysz J., et al. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107. J. Pharmacol. Exp. Ther. 2010, 334:863-874.
26. Marks M.J., et al. Downregulation of nicotinic receptor function after chronic nicotine infusion. J. Pharmacol. Exp. Ther. 1993, 266:1268-1276.
27. Marques-Aleixo I., et al. Physical exercise as a possible strategy for brain protection: evidence from mitochondrial-mediated mechanisms. Prog. Neurobiol. 2012, 99:149-162.
28. McCallum S.E., et al. Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage. Mol. Pharmacol. 2005, 68:737-746.
29. Millar N.S., Gotti C. Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology 2009, 56:237-246.
30. Miller G.W., et al. Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 1999, 20:424-429.
31. Morens D.M., et al. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue?. Neurology 1995, 45:1041-1051.
32. Nicoletti A., et al. Voluptuary habits and clinical subtypes of Parkinson's disease: the FRAGAMP case-control study. Mov. Disord. 2010, 25:2387-2394.
33. Olanow C.W., Schapira A.H. Therapeutic prospects for Parkinson disease. Ann. Neurol. 2013, 74:337-347.
34. Othman A.A., et al. Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers. J. Clin. Pharmacol. 2011, 51:512-526.
35. Pascual A., et al. GDNF and protection of adult central catecholaminergic neurons. J. Mol. Endocrinol. 2011, 46:R83-R92.
36. Perez X.A., et al. {Alpha}6{beta}2* and {alpha}4{beta}2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease. Mol. Pharmacol. 2010, 78:971-980.
37. Picciotto M.R., Zoli M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front. Biosci. 2008, 13:492-504.
38. Quik M., Wonnacott S. {Alpha}6{beta}2* and {alpha}4{beta}2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol. Rev. 2011, 63:938-966.
39. Quik M., et al. Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol. Pharmacol. 2003, 63:1169-1179.
40. Quik M., et al. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends Pharmacol. Sci. 2007, 28:229-235.
41. Quik M., et al. Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov. Disord. 2012, 27:947-957.
42. Ritz B., et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch. Neurol. 2007, 64:990-997.
43. Rosa A.O., et al. Neuroprotection by nicotine in hippocampal slices subjected to oxygen-glucose deprivation: involvement of the alpha7 nAChR subtype. J. Mol. Neurosci. 2006, 30:61-62.
44. Ryan R.E., et al. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice. Br. J. Pharmacol. 2001, 132:1650-1656.
45. Schallert T., et al. Tactile extinction: distinguishing between sensorimotor and motor asymmetries in rats with unilateral nigrostriatal damage. Pharmacol. Biochem. Behav. 1982, 16:455-462.
46. Schallert T., et al. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
47. Shimohama S. Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models. Biol. Pharm. Bull. 2009, 32:332-336.
48. Smeyne M., Smeyne R.J. Glutathione metabolism and Parkinson's disease. Free Radic. Biol. Med. 2013, 62:13-25.
49. Sprenger F., Poewe W. Management of motor and non-motor symptoms in Parkinson's disease. CNS Drugs 2013, 27:259-272.
50. Stuckenholz V., et al. The alpha7 nAChR agonist PNU-282987 reduces inflammation and MPTP-induced nigral dopaminergic cell loss in mice. J. Park. Dis. 2013, 3:161-172.
51. Sullivan J.P., et al. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J. Pharmacol. Exp. Ther. 1997, 283:235-246.
52. Sulzer D., Surmeier D.J. Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov. Disord. 2013, 28:715-724.
53. Sutachan J.J., et al. Cellular and molecular mechanisms of antioxidants in Parkinson's disease. Nutr. Neurosci. 2012, 15:120-126.
54. Suzuki S., et al. 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced Parkinsonian neurodegeneration through alpha7 nicotinic acetylcholine receptor stimulation in rats. J. Neurosci. Res. 2013, 91:462-471.
55. Tanner C.M. Advances in environmental epidemiology. Mov. Disord. 2010, 25(Suppl. 1):S58-S62.
56. Thacker E.L., et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 2007, 68:764-768.
57. Toulorge D., et al. Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+. FASEB J. 2011, 25:2563-2573.
58. Visanji N.P., et al. Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology 2006, 51:506-516.
59. Wang H.Y., et al. beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J. Biol. Chem. 2000, 275:5626-5632.
60. Wirdefeldt K., et al. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 2011, 26(Suppl. 1):S1-S58.
61. Wonnacott S., et al. Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. Eur. J. Pharmacol. 2000, 393:51-58.
62. Yanagida T., et al. Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model. Neurosci. Res. 2008, 62:254-261.
63. Zigmond M.J., et al. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 1990, 13:290-296.